Category: 17321-29-8

17321-29-8, Name is 3-Bromo-6-methoxypyridazine, belongs to pyridazine compound, is a common compound. Recommanded Product: 3-Bromo-6-methoxypyridazineIn an article, once mentioned the new application about 17321-29-8.

5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)-A potent FLAP inhibitor

A series of potent 5-lipoxygenase-activating protein (FLAP) inhibitors are herein described. SAR studies focused on the discovery of novel alicyclic moieties appended to an indole core to optimize potency, physical properties and off-target activities. Subsequent SAR on the N-benzyl substituent of the indole led to the discovery of compound 39 (AM679) which showed potent inhibition of leukotrienes in human blood and in a rodent bronchoalvelolar lavage (BAL) challenge model.

Do you like my blog? If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 17321-29-8

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N2550 – PubChem

 

Electric Literature of 17321-29-8, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.17321-29-8, Name is 3-Bromo-6-methoxypyridazine, molecular formula is C5H5BrN2O. In a Patent£¬once mentioned of 17321-29-8

OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS

A compound of Formula I : (I) or a pharmaceutically acceptable salt thereof, wherein: each R’ is QR1; each Q is independently selected from a bond, -C1-C10 alkylene, -C2-C10 alkenylene, -C(O)-, -C(O)O-, -C(O)N(R1)-, -C(O)N(R1)SO2- -N(R1)C(O)-, – N(R1)-, -N(SO2(R1)), -N(R1)SO2- -C(O)NR4R5-, -N(R4R5)C(O)-, -N(R4R5)- – S-, -SO-, -SO2-, -S(O)O-, -SO2N(R1)- and -O-; each R1 is independently selected from H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 haloalkyl, C1-C10 heteroalkyl, aryl, heteroaryl, C3-C10 cycloalkyl, -(C1-C10 alkylene)-C3-C10 cycloalkyl, halogen, cyano, C1-C10 alkylene- aryl, C1-C10 alkylene heteroaryl, C1-C10 heterocycloalkyl and -(C1-C10 alkylene)- C1-C10 heterocycloalkyl. The compounds are inhibitors of HDAC and therefore have potential utility in the therapy of a number of conditions including cancer and inflammation.

We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 17321-29-8, and how the biochemistry of the body works.Electric Literature of 17321-29-8

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N2543 – PubChem

 

17321-29-8, 3-Bromo-6-methoxypyridazine is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of diisopropylamine(0.74 mL, 5.19 mmol) in THF (15 mL) was added butyl lithium (3.2 mL, 5.12 mmol) at 0 C. The resulting mixture was stirred was stirred for 15 min and the resulting LDA solution was cooled to -78 C . A solution of 3-bromo-6-methoxypyridazine (800mg, 4.23 mmol) in THF (5 mL) was added dropwise to the LDA solution. After 5 min DMF (0.4 mL, 5.17 mmol) was added and the mixture was stirred for lh at -15 C. The reaction mixture was quenched with sat aq. ammonium chloride solution (50 mL) and extracted with EtOAc. The combined organic layers were dried over sodium sulfate, filtered, concentrated under reduced pressure. Purified by flash column chromatography to give the desired product 6- bromo-3-methoxypyridazine-4-carbaldehyde 760 mg).

17321-29-8, As the paragraph descriping shows that 17321-29-8 is playing an increasingly important role.

Reference£º
Patent; MERCK SHARP & DOHME CORP.; ARRINGTON, Kenneth, L.; BURGEY, Christopher; GILFILLAN, Robert; HAN, Yongxin; PATEL, Mehul; LI, Chun Sing; LI, Yaozong; LUO, Yunfu; LEI, Zhiyu; XU, Jiayi; WO2014/58747; (2014); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

 

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.17321-29-8,3-Bromo-6-methoxypyridazine,as a common compound, the synthetic route is as follows.

Under Ar(g), to a mixture of pyrazin-2-amine (1) (209mg, 2.2mmol), 3- bromo-6-methoxypyridazine (2) (378mg, 1.4mmol), Cs2C03 (1.30g, 4.0mmol) was added degassed dry 1 ,4-dioxane (13mL). The reaction mixture was then flushed with Ar(g) for 1 min before Pd2(dba)3 (92mg, 0.1 mmol) and Xantphos (127mg, 0.22mmol) were added. The reaction mixture was heated up to 90C for 40h. It was then cooled down to rt. EtOAc (15ml_), H20 (10mL) and brine (5ml_) were added to the reaction mixture. The organic phase was separated and the aqueous phase was extracted with EtOAc (15ml_). The organic layers were combined and Pd-scavenger (MP-TMT, ~400mg, 1.3mmol/g) was added. This was shaken for several hours followed by filtration. The filtrate was concentrated in vacuo, dissolved in DMSO (4ml_) and purified by basic prep LCMS to yield (3) as a solid (5.4mg, 1 %).

17321-29-8, The synthetic route of 17321-29-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; KARUS THERAPEUTICS LIMITED; SHUTTLEWORTH, Stephen Joseph; GATLAND, Alice Elizabeth; FINNEMORE, Daniel John; ALEXANDER, Rikki Peter; SILVA, Franck; CECIL, Alexander; (233 pag.)WO2019/166824; (2019); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem